Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galinpepimut-S Maintenance in AML CR2/CRp2
2024-516405-23-00Phase 3Authorised
- Sponsor
- SELLAS Life Sciences Group, Inc.
- Start
- Oct 2024
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of galinpepimut-s in acute myeloid leukemia (AML) (2 arms), sponsored by SELLAS Life Sciences Group, Inc. Primary endpoint: Median overall survival. Planned start Oct 2024; status: authorised.
02
Drugs
galinpepimut-s
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-516405-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516405-23-00.